Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
uk.investing.com on MSN9h
Germany shares higher at close of trade; DAX up 1.26%Germany equities were higher at the close on Thursday, as gains in the Technology, Telecoms and Media sectors propelled ...
Hosted on MSN9h
Germany stocks higher at close of trade; DAX up 1.26%added 4.64% or 1.37 points to end at 30.76 and Deutsche Telekom AG Na (ETR:DTEGn) was up 3.30% or 0.92 points to 28.77 in ...
MERCK & Co licenced an experimental cancer antibody from a closely held Chinese company in a deal worth US$588 million ...
The annual inflation rate in Sweden stood at 1.6% in October. On the corporate front, major European companies, including ...
European markets are heading for a mixed open Thursday as traders assessed the global inflation outlook and the possible ...
On Tuesday, Merck & Co Inc (MRK) stock saw a decline, ending the day at $98.58 which represents a decrease of $-2.15 or -2.13% from the prior close of $100.73. The stock opened at $100.76 and touched ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
SAN ANTONIO -- Research presented at the ObesityWeek annual meeting included studies on rationing of prescription medications ...
Bernstein has recently initiated Merck & Co Inc (MRK) stock to Mkt Perform rating, as announced on October 17, 2024, according to Finviz. Earlier, on March 11, 2024, Societe Generale had reduced the ...
Deutsche Bank lowered the firm’s price target on Merck (MRK) to $140 from $145 and keeps a Buy rating on the shares following the Q3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback